Rob Collin (Dept. of Human Genetics) and Carel Hoyng (Dept. of Ophthalmology), theme Sensory disorders, have received a prestigious award from the Translational Research Acceleration Program of the Foundation Fighting Blindness USA.
This program is dedicated to further translate innovative therapeutic proof-of-concept to patients with retinal disease. With this three-year award, Rob and Carel, together with their team of collaborators, aim to bring antisense oligonucleotide-based splicing modulation therapy for patients with Stargardt disease up to the phase of clinical testing.
Related news items
![](https://www.radboudumc.nl/getmedia/7f385711-56ce-4027-85c3-5ecd6993299f/RNA-molecuul.aspx?width=2308&height=1298&ext=.jpg&type=BlockColumn1Zoom1)
Surprisingly dominant cause underlying type I congenital defect of glycosylation
21 October 2021 Alex Garanto, Melissa Bärenfänger, Mirian Janssen, and Dirk Lefeber published a new study, identifying a surprisingly dominant genetic cause underlying type I congenital defect of glycosylation with neuromusculoskeletal phenotypes. read more![](https://www.radboudumc.nl/getmedia/c31cde39-be85-4e2e-9bb0-f6d477441b0c/Brein2.jpg.aspx?width=500&height=283&ext=.jpg&type=BlockColumn1Zoom1)
Treatment of brain diseases at risk if neuroscientists can no longer conduct their research
5 August 2021 In order to treat brain diseases such as depression, Alzheimer's or ADHD, more research into the brain is needed. read more![](https://www.radboudumc.nl/getmedia/859af945-0706-4912-8fc1-00686dae5513/stargardt_eye_medicine_1.aspx?width=600&height=350&ext=.jpg&type=BlockColumn1Zoom1)
Retina-on-chip modeling and treating eye diseases in a dish
10 June 2021 Alex Garanto, together with Anneke den Hollander and Andries van der Meer (UTwente) have received 1,17M€ to develop a retina-on-chip model to improve our understanding in eye diseases and to develop treatments against them. read more![](https://www.radboudumc.nl/getmedia/078b27c5-078c-4623-b148-e6942f9186b1/Eye.aspx?width=4000&height=2400&ext=.jpg&type=BlockColumn1Zoom1)
Innovative therapy developed for the future treatment of hereditary (deaf)blindness
26 May 2021 Researchers from the department of Otorhinolaryngology, headed by Erwin van Wijk, developed a novel therapeutic strategy to halt the progression or to prevent vision loss in patients as a consequence of USH2A exon 13 mutations. read more![](https://www.radboudumc.nl/getmedia/0fb45339-b0c5-420b-bb90-7f0f317809a4/Rob-Collin.aspx?width=299&height=184&ext=.jpg&type=BlockColumn1Zoom1)
Rob Collin appointed Professor of Molecular therapy for inherited retinal diseases
3 February 2021 Effective 16 January 2021, molecular geneticist Rob Collin has been appointed Professor of 'Molecular Therapy for Inherited Retinal Diseases' at Radboudumc Radboud University. read more![](https://www.radboudumc.nl/getmedia/ce2d3fcd-6d7e-4ff3-8d5f-418705f4c852/novartis-grant.aspx?width=382&height=230&ext=.png&type=BlockColumn1Zoom1)